- Home
- Reports Store
- Medical Devices
Cardiac Monitoring & Rhythm Management Devices Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0005 |
|---|---|
| Report Code | CM-MD-P1-1005 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Devices / Monitoring Episodes / Implants |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

Cortex Meridian Research values the Cardiac Monitoring & Rhythm Management Devices market at approximately USD 30.0 billion in 2025, with the market expected to reach about USD 56.3 billion by 2035 at a CAGR of 6.5%. The key change is that cardiac care is moving from episodic diagnosis and device implantation toward continuous, connected management. Revenue is increasingly generated across the patient lifecycle—from ambulatory ECG detection to implantable therapy and remote follow-up.
Traditional pacemakers, ICDs and CRT systems still account for the majority of market value, but faster growth is emerging in leadless pacing, mobile telemetry, patch ECG and implantable loop recorders. These technologies expand the addressable population and create more data-intensive models of care. Hospitals and electrophysiology practices also benefit from remote monitoring because it can reduce unnecessary in-person checks and improve early detection of device or rhythm issues.
Abbott’s AVEIR platform is central to current competitive momentum because dual-chamber leadless pacing opens a larger clinical population than single-chamber systems. Medtronic’s Micra platform remains a strong benchmark, while iRhythm and other digital-monitoring specialists are increasing competition upstream in diagnosis. The commercial implication is that market leadership will depend increasingly on the ability to connect detection, therapy and follow-up within one ecosystem.
Report Description
The Cardiac Monitoring & Rhythm Management Devices Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
Arrhythmia burden, remote monitoring, AI-enabled ECG analytics, wearables, aging populations and device replacement cycles.
Restraints / Risks
Data integration, cybersecurity, reimbursement, false positives, device recalls and competition from consumer wearables.
Opportunities
Patch ECG, mobile telemetry, implantable monitors, AI triage, remote device management and leadless/MRI-compatible rhythm devices.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope
By product: ECG, Holter, event monitors, mobile cardiac telemetry, implantable loop recorders, pacemakers, ICDs, CRT; by connectivity: wired/wireless; by end user: hospitals, ASCs, clinics, home/remote monitoring; by geography.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: market size; procedure volumes; ECG/ambulatory monitoring/CRM penetration; FDA pipeline; reimbursement; Abbott/Medtronic/Edwards/Boston Scientific competition. 2. Canada: procedure volumes; structural heart; CRM; provincial reimbursement; hospital procurement. 3. UK: NHS cardiology capacity; PCI/TAVR; rhythm management; waiting lists; procurement; reimbursement. 4. Germany: high procedural density; TAVR; EP/CRM; reimbursement; hospital adoption; supplier competition. 5. France: structural heart; interventional cardiology; reimbursement; hospital volumes; device adoption. 6. Italy: remote monitoring/CRM demand; regional hospital capacity; reimbursement; procurement. 7. Spain: cardiac procedure volumes; monitoring/CRM; public hospital procurement; reimbursement. 8. Netherlands: advanced structural-heart and EP adoption; high-value devices; digital monitoring. 9. Switzerland: premium cardiovascular technologies; private/public hospital mix; structural heart; CRM. 10. China: PCI volume; TAVR growth; local device companies; volume-based procurement; pricing; regulatory approvals. 11. India: high CAD burden; PCI; TAVR growth; price caps; domestic manufacturing; hospital expansion. 12. Japan: aging population; TAVR/CRM; reimbursement; domestic and multinational competition. 13. South Korea: advanced cardiac intervention; TAVR/EP; reimbursement; hospital technology adoption. 14. Australia: ECG/ambulatory monitoring/CRM; reimbursement; cardiac centers; remote monitoring. 15. Brazil: PCI and rhythm management; public/private access; import pricing; hospital concentration. 16. Argentina: cardiology procedures; import dependency; pricing; reimbursement; private hospitals. 17. Saudi Arabia: cardiac center investment; PCI/TAVR; Vision 2030; tenders; localization. 18. UAE: premium cardiology services; structural heart; private hospitals; technology adoption. 19. South Africa: public/private cardiology split; PCI/CRM access; reimbursement; distribution.
Competitive Landscape & Companies Covered
Medtronic; Abbott; Boston Scientific; Philips; GE HealthCare; ZOLL; BIOTRONIK; Nihon Kohden; MicroPort; iRhythm
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include Patch ECG, mobile telemetry, implantable monitors, AI triage, remote device management and leadless/MRI-compatible rhythm devices.
Executive Summary
The Cardiac Monitoring & Rhythm Management Devices market is estimated at USD 30.0 billion in 2025 and is projected to reach approximately USD 56.3 billion by 2035 at a CAGR of 6.5%. Growth is being driven by the convergence of implantable therapy with remote monitoring, allowing vendors to capture more value across the patient journey.
Abbott’s AVEIR expansion and Medtronic’s Micra franchise are accelerating leadless pacing, while ambulatory monitoring providers are broadening access to diagnosis outside hospitals. The market is therefore evolving from a hardware-only category into a connected-care ecosystem where devices, data and recurring monitoring services all contribute to revenue.
Key Takeaways
- 2025 Cortex normalized estimate: USD 30.0 billion
- 2035 normalized outlook: USD 56.3 billion
- Normalized 2025–2035 CAGR: 6.5%
- Key growth drivers: Arrhythmia burden, remote monitoring, AI-enabled ECG analytics, wearables, aging populations and device replacement cycles.
- Priority opportunity areas: Patch ECG, mobile telemetry, implantable monitors, AI triage, remote device management and leadless/MRI-compatible rhythm devices.
- Primary competitive set: Medtronic; Abbott; Boston Scientific; Philips; GE HealthCare; ZOLL; BIOTRONIK; Nihon Kohden; MicroPort; iRhythm
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global Cardiac Monitoring & Rhythm Management Devices market size? A: Cortex Meridian Research estimates it at approximately USD 30.0 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 56.3 billion, based on a 6.5% CAGR assumption.
Q: What are the major growth drivers? A: Arrhythmia burden, remote monitoring, AI-enabled ECG analytics, wearables, aging populations and device replacement cycles.
Q: Which opportunities should suppliers prioritize? A: Patch ECG, mobile telemetry, implantable monitors, AI triage, remote device management and leadless/MRI-compatible rhythm devices.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0005 · CM-MD-P1-1005 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
